Patent · US Active

Modified RSV F proteins and methods of their use

US10022437B2 · kind B2 · utility

17Cited by

4References

16Claims

0Family size

Assignee

Novavax, Inc. · US

Inventors

Peter Pushko · Frederick, US
Yingyun Wu · Clarksburg, US
Michael J. MASSARE · Mount Airy, US
Ye Liu · Foster City, US
Gale Smith · Germantown, US
Bin Zhou · Clarksburg, US

Key dates

Filing date	Aug 28, 2015
Grant date	Jul 17, 2018
Priority date	—
Expiry date	Aug 28, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18571
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.